Understanding Adrenal Cancer
A guide for adults who have been told that an adrenal tumor may be adrenocortical carcinoma. It is rare, and it is treated with surgery at an experienced center. Some patients also take a drug called mitotane.
Welcome
Adrenocortical carcinoma is rare, about 1 to 2 people per million each year. Most family doctors, and even most cancer doctors, will see only a few cases in a whole career. The same is true of most hospitals. So the best thing you can do in the first few weeks is to get to a high-volume center (see Chapter 5) for surgery and follow-up.
It is also a serious cancer. It often grows quickly, and it can push into nearby organs or spread to other parts of the body. The treatment plan, though, is well established: surgery first, then mitotane for patients at higher risk of the cancer coming back.
Two decisions matter more than almost anything else. The first is that your surgery happens at a center that sees ACC cases regularly, with a surgeon who has done many of these operations. The second is that the team around you, surgery, endocrinology, medical oncology, pathology, radiology, all see your case together. This guide walks through both of those, along with the workup, the operation itself, the drug mitotane, chemo when it comes into play, gene testing, and what daily life looks like along the way.
This guide is made to sit next to two others in the WellPrept library. The Cancer Basics guide covers the words and ideas that come up with any cancer diagnosis. The Adrenal Mass guide covers the wider workup of any adrenal finding, most of which turn out to be benign. If you have not read those yet, doing so first will make this guide easier to follow.
How to use this guide. Read through it at your own pace, highlighting parts that match what you have been told and skipping past what does not apply. The question list in Chapter 13 is meant to be brought to your next visit on paper or on your phone. You are not expected to retain all of this, only to know where to look when something comes up.
What adrenocortical carcinoma is
Adrenocortical carcinoma, or ACC, is a cancer that starts in the cortex, the outer layer of the adrenal gland. It is rare and aggressive. Outcomes are better when an experienced team runs your care.
The gland and what it does
You have two adrenal glands, small triangle-shaped glands that sit on top of each kidney. The outer part, the cortex, normally makes three kinds of hormones: cortisol (a stress hormone), aldosterone (which controls salt and blood pressure), and androgens (male-type hormones that both men and women make). When cells in the cortex become cancerous, they often keep making one or more of those hormones. They also tend to grow into a large mass.
How rare it really is
About 1 to 2 people per million are diagnosed with ACC each year. In the United States, that means roughly 300 to 600 new cases a year. For comparison, prostate cancer has about 300,000 new cases a year. Most general urologists, endocrinologists, and oncologists see only a few cases of ACC over an entire career. That is why care at a center that sees this disease often matters so much.
Many ACCs make hormones
Roughly 6 out of 10 ACCs make excess hormones. Which symptoms show up depends on which hormone the tumor makes.
- Cortisol-making ACC. Can cause weight gain in the trunk and face, easy bruising, purple stretch marks, high blood sugar, muscle weakness, mood changes, and high blood pressure. Doctors call this Cushing syndrome.
- Androgen-making ACC. Can cause new facial hair, a deeper voice, irregular periods, or male-pattern hair loss in women. This is sometimes the first sign that brings a patient in.
- Mixed cortisol and androgen. Common in ACC. A benign adrenal tumor tends to make just one hormone, if any, so a mixed pattern points toward ACC.
- Aldosterone or estrogen-making ACC. Less common. Tumors that make estrogen can cause female-type changes in men.
- Nonfunctioning ACC. About 4 out of 10 make no extra hormones. They are found through pain, a lump you can feel, or a finding on a scan done for another reason.
Often large at diagnosis
Most ACCs are larger than 6 cm when they are found, which is more than 2 inches across. Some are smaller and caught early when scans are done for another reason. The cancer tends to grow into nearby parts (the kidney, the liver, the large vein that returns blood to the heart). It can spread to the lungs, liver, bone, and lymph nodes.
Many ACCs are first picked up on a scan done for another reason. Most adrenal masses found this way are benign. ACC is the uncommon case where the scan features are concerning.
How it is found and worked up
ACC is usually found in one of three ways: through symptoms of hormone excess, through symptoms from the tumor's size or spread, or as a surprise on a scan. The workup that follows is the same, no matter which way it was found.
Imaging that goes deeper than a normal scan
A regular CT may have started this. The next step is usually a dedicated adrenal-protocol CT. This is a CT done with a specific pattern of contrast timing that helps your team tell a benign adrenal tumor from one that is more concerning. MRI of the belly is often added. MRI helps map any growth of the tumor into a large vein and is used when contrast dye is not safe.
On scans, several signs can raise concern for ACC. These include a tumor more than 4 to 6 cm, jagged edges, dead tissue or blood inside the mass, and a dense look on a no-dye scan. Other signs are slow loss of dye, no clean gap between the mass and a nearby organ, growth into a vein, large lymph nodes, or a spot in the lung or liver. Your team reads the whole picture rather than any single number.
A PET-CT is sometimes added when cancer is suspected. ACC usually lights up on PET, and the scan can also pick up distant spread that changes the plan.
A full hormonal workup, before anything else
Every patient with a possible ACC needs a full set of hormone tests before surgery. This is not optional. The pattern of hormones the tumor makes affects both the diagnosis and how your surgery is planned.
- Cortisol testing. A test called the dexamethasone test checks for too much cortisol.
- Metanephrines. A blood or urine test to rule out another adrenal tumor called a pheochromocytoma (a tumor that makes adrenaline). A surgery or biopsy on a missed pheo can send blood pressure into a crisis.
- Androgens and steroid building blocks. A panel of male-type hormones. High levels point to ACC over a benign tumor.
- Aldosterone and renin. Checked when blood pressure is hard to control or potassium is low.
A pattern of mixed hormones, or excess steroid building blocks, is itself a clue to ACC. A complete panel tells the team more than any single test.
Basic labs and a baseline
Along with the hormone tests, you also get standard blood work. It covers your blood counts, kidney and liver numbers, salt and calcium levels, and a starting blood pressure.
You can request a CD of your imaging and copies of your radiology and lab reports. Bring them with you to any second opinion. It saves time and makes sure another team is reading the same studies.
Why biopsy is usually avoided
Patients often ask why a needle biopsy cannot just settle whether the tumor is cancer. For a suspected ACC, the tissue answer usually comes from the pathology after surgery, and a needle biopsy carries risks that outweigh what it adds.
Two reasons your team steers away from biopsy
1. Safety, when pheochromocytoma has not been ruled out. Pheochromocytoma is a different adrenal tumor that pumps out chemicals that drive blood pressure. Sticking a needle into one can trigger a dangerous spike in blood pressure. Any biopsy of an adrenal mass requires negative metanephrine testing first.
2. Risk of seeding the needle path with cancer cells. This is the bigger reason in suspected ACC. When the needle passes through the tumor and back out, cancer cells can be left along the track. This can turn a cancer that surgery could have cured into one that is harder to control. Most major guidelines now advise against routine biopsy in suspected ACC.
How the diagnosis usually gets made instead
Three things answer the question without a biopsy: how the tumor looks on scans, the hormone results, and the final lab work after the tumor is removed. The pathologist (the doctor who reads tissue under a microscope) confirms the diagnosis on the piece taken out.
When biopsy still has a role
Biopsy is reserved for selected cases. The most common one is when your team suspects the adrenal mass is a metastasis from a different cancer you already have (for example, lung or kidney cancer). In that case the answer changes the treatment plan, and a biopsy is reasonable. Your team will tell you if this fits your situation.
Sometimes a biopsy was done before ACC was on the radar. If that happened to you, tell your surgical team. The plan can still go forward, and high-volume centers know how to manage this.
How the pathologist confirms ACC after surgery
After surgery, a pathologist looks at the tumor under a microscope for signs that tell ACC apart from a benign tumor. These signs are scored on a 9-point system called the Weiss score. A score of 3 or more fits ACC. The pathologist also checks how fast the cells are dividing (Ki-67), whether the edges of the cut were clean, and whether nearby tissue or lymph nodes were involved.
ACC is rare, so a pathology second opinion at a high-volume adrenal cancer center is reasonable. Ask for one if the local read is unclear.
Stage and what it means
ACC has its own staging system, called ENSAT. It is similar to the TNM system used in many other cancers, but tailored to how ACC spreads. Your stage drives the plan and the outlook.
The four stages
Why stage matters
Stage at diagnosis is the strongest single predictor of outcome in ACC. It also drives whether you are offered mitotane after surgery and how often you get scans for the first few years. Learn your stage by name (Stage I, II, III, or IV) and write it down where you keep your notes.
Other things that shape outlook beyond stage
- Margin status. Whether the cancer was fully out (called R0), present at the edge under a microscope (R1), or left behind in plain view (R2). A complete R0 removal is the goal. It depends heavily on the surgeon and the approach used.
- Ki-67 index. The share of cells that are dividing. Higher numbers point to a faster tumor.
- Tumor grade and Weiss score features.
- Cortisol-making tumors. Tend to do a bit worse than tumors that make no hormones.
- How quickly the team can get you to treatment.
- Your overall health and age.
On your next visit you can ask: "What is my ENSAT stage, and how does that shape what you are recommending?" If the answer is not clear, ask your team to walk you through it again.
The high-volume center decision
For ACC, where you have the operation matters as much as which operation you have. Taking a couple of weeks to set it up well is a reasonable use of time, even when you feel pressure to move fast.
Why this matters more in ACC than in most cancers
The data here is consistent across decades and across countries. ACC patients operated on at centers that handle the cancer often have better results. They have more clean removals, fewer surgical problems, and longer survival. The operation involves a large tumor that may be stuck to the kidney, the vena cava, the liver, or the diaphragm. The hardest calls are how much to take out and how to handle the vein. A surgeon gets better at these by doing them often.
The phrase "high-volume center" sounds like it means an academic medical center in a major city, and it often does. Because ACC is rare, a center that does 10 to 20 adrenal surgeries a year with a meaningful number of true ACC cases qualifies. Most patients end up at a comprehensive cancer center, a major endocrine surgery program, or a large academic urology or general surgical oncology division.
What a high-volume center brings
- Surgeons who do these often. This can be a cancer surgeon who focuses on the adrenal gland, an endocrine surgeon, or a urologic cancer surgeon.
- Team case review (tumor board). A team that goes over each ACC case together: surgery, medical oncology (cancer medicine), endocrinology (hormones), radiation oncology, pathology, and radiology (imaging), all in one room.
- Pathologists who know ACC. The Weiss score and other clues can be subtle.
- Endocrinologists (hormone doctors) who know mitotane. Mitotane is hard to dose and manage, and a team that uses it often will get you to the target blood level with fewer setbacks.
- Vein and liver surgeons on standby. Some ACCs need help from teams beyond the adrenal surgeon.
- Clinical trials on site. ACC trials are mostly at high-volume centers.
Questions to ask a center you are considering
- How many adrenal surgeries does your center do each year, and how many for ACC?
- How many ACC surgeries have you done in the past few years?
- Will my case be reviewed at a team tumor board?
- Is there an endocrinologist (hormone doctor) on the team who works with mitotane?
- Do you have a pathologist on staff who knows ACC?
- Are there ACC clinical trials open here?
If you were told about ACC at a local hospital, ask for a second opinion at a high-volume adrenal cancer center. That is almost always the right next step, even when it means travel. Most teams expect this and will help send records.
Surgery: open en-bloc resection
The goal of ACC surgery is to remove the whole tumor with clean edges on the first operation. The chance of cure drops sharply if cancer is left behind or spilled. For most ACC the standard approach is open surgery, with the tumor taken out together with any nearby tissue it has reached.
Open versus laparoscopic, and why this matters
For benign adrenal tumors and small low-risk masses, keyhole (laparoscopic) surgery is the standard. ACC is different. When ACC is known or strongly suspected, open surgery is the default in most cases. A minimally invasive (laparoscopic or robotic) approach is used only for smaller tumors with no sign of spread, and only by surgeons who do many of these.
The reasons are about cancer control:
- Tumor rupture risk. ACC tumors can be large, soft, and full of blood. Handling them through small cuts raises the chance of breaking the outer shell. Spilled cancer cells make outcomes worse.
- Clean margins. When the tumor has grown into nearby tissue, the best chance of clean edges comes from taking it out as one piece with that tissue. This is called en-bloc resection.
- Local return. After keyhole surgery for ACC, the cancer comes back nearby more often in most reports. This holds true even in skilled hands.
- Vein control. Some ACCs grow into the kidney vein or the large vein that returns blood to the heart. Open surgery is needed for safe control there.
- Nearby organs. A few may come out with the tumor. These can be the kidney, spleen, part of the liver, the tail of the pancreas, or part of the diaphragm.
A small group of carefully chosen, contained, small ACCs may be done this way, in the hands of a surgeon with deep ACC and keyhole skill. If your team suggests it for you, ask why it fits your case.
What the operation involves
- General anesthesia.
- An open cut in the upper belly or side, based on where the tumor sits.
- En-bloc removal. The gland, the tumor, and any tissue it has reached all come out as one piece.
- Lymph node removal in the area, in most cases. This helps with staging and may also help control the cancer.
- Vein repair if a vein was involved.
- Hospital stay of 5 to 10 nights, longer if a vein was rebuilt or several organs were taken out.
- Recovery of several weeks to a couple of months, based on what was done.
Risks to know about
The main risks are bleeding, injury to nearby organs, tumor spill, and infection. Others are lung problems from a large cut, blood clots, and the usual anesthesia risks. Patients with cortisol-making tumors will need steroid pills for a time after surgery. The other adrenal gland has been quiet, and it needs time to wake back up.
The best chance to control ACC is a complete removal with clean edges (R0) and no tumor spill, done at the first operation. A repeat surgery after spill or cancer left behind is harder and works less well.
Mitotane after surgery
Mitotane is a pill that targets adrenal cortex cells, and it is the only drug aimed specifically at ACC. If it is in your plan, it will be a major part of your daily life for at least two years.
What mitotane is, and what it does
Mitotane (brand name Lysodren) is a pill that damages adrenal cortex cells. It has been used for ACC since the 1960s and is still the only drug aimed specifically at this cancer. After surgery, it is given to patients with a higher risk of the cancer coming back (called adjuvant mitotane), and it is also part of care for advanced disease.
Who is offered adjuvant mitotane
The decision is shared with your team. Features that favor adjuvant mitotane include:
- Stage III disease (locally advanced or with lymph nodes).
- Positive or uncertain margins after surgery.
- A high Ki-67 (typically above 10%).
- Tumor rupture during surgery.
- High-grade pathology features.
For lower-risk patients (stage I or II, fully removed, low Ki-67), a recent trial called ADIUVO showed that the chance of return is low. For them, watching alone may be a reasonable plan. The call is made with an ACC-experienced team that weighs your own risk.
What taking it involves
Mitotane is taken by mouth, usually multiple times a day, building up the dose over weeks. Your team checks drug blood levels regularly. The target level (often 14 to 20 mg/L) is associated with better outcomes but takes patience to reach. Treatment is typically continued for at least 2 years, and often longer.
Side effects
Mitotane is one of the harder cancer drugs to take. Most people on full doses feel a mix of the symptoms below at some point, and the team usually spends the first few months adjusting dose and supportive medications to find a level that works.
- Loss of adrenal function. Mitotane wipes out the adrenal cortex on purpose. So nearly every patient on it needs cortisol pills (glucocorticoid), usually hydrocortisone. Many also need a salt-balance pill (mineralocorticoid) called fludrocortisone. You start these at the beginning of mitotane and take them the whole time you are on the drug. You keep taking them well after mitotane stops, because the adrenal glands take a long time to start working again. For most people this is lifelong. The body uses up steroid pills faster on mitotane, so the doses are often higher than usual.
- Stomach symptoms. Nausea, throwing up, loose stools, and belly pain are common. They often cap how much you can take.
- Brain and balance. Tired feeling, dizzy spells, shaky walk, foggy thinking, and slurred speech. More so at higher blood levels.
- Liver test changes. Tracked on labs.
- Skin rash.
- High cholesterol and triglycerides.
- Effects on thyroid, sex hormones, and vitamin D. Tracked and replaced as needed.
- Drug interactions. Mitotane shifts how the body handles many other drugs. Your other prescriptions may need new doses.
- Not safe in pregnancy. Mitotane causes birth defects. Reliable birth control is required while you take it.
If you are on mitotane, or had a cortisol-making tumor taken out, you need to know your exact steroid dose, when to take stress doses (for fever, surgery, throwing up), and what to do if you cannot keep pills down. Wear a medical alert bracelet. Carry a card that says you need steroids. This is the most important safety step on mitotane.
Adjuvant radiation, in select cases
Radiation to the tumor bed is sometimes added after surgery for patients with a high risk of local return: dirty margins, tumor spill, or local spread. The call is made by your team with input from a radiation doctor. It is not a standard part of every plan.
Living through treatment
ACC treatment runs for years. Most patients bring a family member to the visits that matter.
The length of ACC care
ACC care usually runs for years rather than months. Surgery comes first, then months of mitotane, scans every three months, and ongoing endocrinology visits. Energy, mood, and sleep drift over the course of the year in ways that are easy to miss visit-to-visit. Keep a short note on your phone about how you have been feeling between visits and bring it in, since the slow changes are usually more useful to your team than the sharp ones.
What happens to cortisol after surgery
If your tumor was making cortisol, you have probably felt run-down, anxious, or low for months without knowing why. After surgery, cortisol levels return to normal. As that happens, mood, sleep, energy, and weight all change again over weeks to months. It helps to add a therapist or a psychiatrist who has worked with cancer patients, even just for a few sessions.
Loneliness of a rare diagnosis
Most patients with ACC will not meet another ACC patient in person. The local cancer support groups at the hospital are usually built around breast, prostate, lung, and colon cancer. Those talks help, but only up to a point. Online communities are where most patients find someone whose story matches their own. NORD, the National Organization for Rare Disorders, keeps a list of adrenal cancer resources. There are also active patient groups on Facebook and Reddit. Your nurse navigator can usually make an introduction, and most centers will connect you with a current patient if you ask.
Palliative care belongs early
Palliative care is symptom-focused care that runs alongside cancer treatment from the start. It helps with pain, nausea, fatigue, sleep, mood, and family talks that are hard to have on your own. Hospice is a different kind of care. ACC is an aggressive cancer with few late-line options, so most teams suggest a palliative care visit in the first few months. Some patients turn down the referral because the word sounds like the team has given up. It does not mean that, and you can ask for the referral yourself.
Money, work, family
Mitotane, chemotherapy, and the imaging schedule are expensive, even with insurance. Co-pay help, foundation grants, and your cancer center's social worker can cover a lot of this, so ask early. The Family and Medical Leave Act protects time off in many jobs. Your social worker can tell you what applies to yours.
Fertility, if it applies
Mitotane causes birth defects and chemotherapy can affect fertility. If you might want children, ask about sperm or egg banking before treatment starts.
Hospice is comfort-focused care when treatment for control of the cancer is no longer being pursued. It does not mean death is imminent. Many people on hospice live longer and more comfortably than they would have without it.
If the cancer is advanced
For ACC that has spread or come back after surgery, the standard backbone of treatment is chemotherapy combined with mitotane. There are fewer options than for more common cancers, so clinical trials come up early in the conversation.
EDP plus mitotane is the standard first-line
For ACC that has spread or come back, the standard first plan is a chemo mix called EDP-M chemo (etoposide, doxorubicin, cisplatin, plus mitotane). This came out of a trial called FIRM-ACT. The trial showed a better response rate and a longer time before the cancer grew, compared with an older chemo mix.
What treatment involves:
- Chemo is given by IV in cycles, every 3 to 4 weeks.
- Mitotane is taken by mouth the whole time.
- Anti-nausea drugs, shots to boost blood counts, and checks on heart, kidney, and nerve health are part of the plan.
In the original trial, about 1 in 4 patients responded, and long-lasting responses are uncommon. EDP-M is still the first-line standard for patients well enough to take it. That is mostly because nothing has yet beaten it in a head-to-head trial.
If first-line stops working
Second-line choices are fewer. They often use a new chemo mix, a single drug, or a clinical trial.
- Streptozotocin with mitotane. An older choice used in this setting.
- Gemcitabine-based mixes.
- Targeted therapy. Only when a tumor test finds a change that has a matching drug. This is rare in ACC.
- Clinical trials. Ask about them at every step. ACC trials are mostly at high-volume centers.
Immunotherapy is a clinical trial question for most patients
Immune drugs (called checkpoint inhibitors, like pembrolizumab or nivolumab) have been studied in ACC. In most patients the effect is small. One group does better: tumors with high MSI or with broken mismatch repair (a DNA repair flaw). ACC tumors that test positive for these features should also be checked for Lynch syndrome (see Chapter 10).
Cortisol-making ACC complicates this. High cortisol can blunt how immune drugs work. Teams may lower cortisol with mitotane or other drugs before or with immunotherapy. Outside of MSI-high disease or a clinical trial, an immune drug on its own is not standard treatment in ACC.
Local treatments for selected spots
When the cancer has spread to only one or a few places, your team may add a local treatment on top of body-wide care:
- Surgery to take out one or a few spots. Most often used for slow-growing, small disease.
- Stereotactic body radiation. Aimed, high-dose radiation in a few visits. Used for spots in lung, liver, or bone.
- Ablation. Heat or cold sent through a needle to kill a small spot.
- Bone-strengthening drugs. Such as zoledronic acid or denosumab. They lower the chance of breaks from bone spots.
- Comfort radiation. For painful spots that need quick relief.
Genes, family, and testing
ACC is linked to inherited cancer syndromes more often than most adrenal masses. Genetic testing is offered to almost every patient. The results can change what your relatives do too.
Why testing is offered to almost everyone
Up to half of childhood ACC, and a fair share of adult ACC, comes from an inherited cancer syndrome (a gene change passed down in families). Major guidelines now say to offer germline (inborn gene) testing to nearly all ACC patients. This is true above all for younger patients. It also applies to anyone with a family history of linked cancers.
Syndromes that come up in ACC
- Li-Fraumeni syndrome (TP53). The strongest single inherited link to ACC. People with a TP53 change have much higher risks of childhood ACC, breast cancer, sarcomas, brain tumors, and several others. Any ACC, especially in a younger adult, should prompt TP53 testing.
- Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM). Best known for colon and uterine cancer risk. Also raises ACC risk. ACC tumors that test as MSI-high or mismatch-repair-deficient on a tumor test should trigger germline Lynch testing.
- MEN1. A family pattern of tumors. They show up in the parathyroid, pancreas, pituitary, and at times the adrenal gland.
- Beckwith-Wiedemann syndrome. Mostly seen in childhood ACC.
- Other rare syndromes. Carney complex, neurofibromatosis type 1, and a growing list of less-defined gene patterns found on wider gene tests.
What a positive result can change
- Watching for other cancers. Plans differ by syndrome. They are built to catch other cancers early.
- Testing for relatives. This is the biggest reason to test. Blood relatives can be offered the same test. Relatives who turn out to carry the same gene change can start their own watch plan years earlier.
- Treatment choices in some cases. For example, MSI-high disease and the chance to use immune drugs.
- Family planning. Such as gene tests before pregnancy and advice during it.
Counseling first, in most cases
Your team will send you to a trained genetic counselor. The visit covers which genes are tested, what each result means, the impact on relatives, insurance points, and the weight of a positive result. A federal law called GINA blocks health insurance and employers from using your gene test results against you. GINA does not cover life, disability, or long-term care insurance. A counselor will walk you through this.
Tumor (somatic) testing
This is different from germline (inborn) testing. Tumor testing looks at the cancer tissue itself for changes that might match specific drugs or trials. In ACC, common findings are TP53, CTNNB1, and others. If the tumor is MSI-high or has broken mismatch repair, your team should also test for Lynch syndrome.
If a family gene syndrome shows up, your blood relatives can be tested and put on a watch plan. It is hard news to share, and the counselor can help you find the right words.
Surveillance and when to call
ACC follow-up is heavier than most cancers in the first two to three years, because that is when the cancer is most likely to come back. The scan schedule eases over the years that follow. Some symptoms, listed below, need a phone call to your team the same day rather than a wait for your next routine visit.
What follow-up looks like after surgery
- Scans. CT of the chest, belly, and pelvis (or MRI of the belly) every 3 months for the first 2 years. Then every 3 to 6 months for years 3 to 5. Then less often. Many teams keep up some scans for at least 10 years, since ACC can come back late.
- Hormone checks. If your tumor made hormones, routine checks of those hormones can catch a return before scans do.
- Hormone doctor visits. Ongoing for patients on steroid pills or mitotane.
- Mitotane checks. Drug blood levels, salts, liver tests, blood fats, thyroid checks.
- Bone density. For patients on steroids long-term.
- Heart risk. Mostly in patients who had too much cortisol before.
Signs of low cortisol: deep weakness, nausea, throwing up, low blood pressure, foggy thinking, or fever in a patient on steroid pills or mitotane. This can turn into a crisis. Take a stress dose of your steroid and call now. Also: bad belly or flank pain; high fever (above all during chemo); wound redness, fluid, or opening after surgery; sudden leg swelling, chest pain, or short breath; a new bad headache or vision change.
Go to the ER for
- Severe trouble breathing.
- Crushing chest pain.
- Severe back pain with new leg weakness or new bowel or bladder changes. This can mean the spinal cord is being pressed and is an emergency.
- Severe bleeding.
- New one-sided weakness or trouble speaking.
- A seizure or any change in how clearly you can think.
- Cannot keep steroid pills down, with throwing up and weakness.
Survivorship topics
- A written survivorship care plan: a summary of your diagnosis, treatments, follow-up plan, and late effects to watch for. Ask for one if you are not offered one.
- Heart and bone health, above all if you had too much cortisol or long-term steroids.
- Watching for other cancers, if a family gene syndrome was found.
- Mental health help if worry, low mood, or scan fear are getting in the way.
- Family gene tests if a syndrome was found.
Survival numbers, in plain terms
Most patients look up survival numbers within a few days of the diagnosis. The numbers that come up first on a search are often older, drawn from broad averages, and easy to read the wrong way. This chapter is a way to read the published numbers against your own situation.
Stage drives the numbers
Here are 5-year survival ranges by stage, drawn from large ACC databases. These are group averages, and your own path may sit above or below the range.
| Stage | 5-year survival range | What it tends to mean |
|---|---|---|
| Stage I | Roughly 60 to 80% | Small tumor, confined, completely removed. Long-term survival is common. |
| Stage II | Roughly 50 to 60% | Larger tumor, still confined. Outcomes depend strongly on a clean R0 resection. |
| Stage III | Roughly 20 to 50% | Locally advanced or with nodes. Treatment is multimodal: surgery, often mitotane, sometimes radiation. |
| Stage IV | Less than 15% | Distant spread at diagnosis. Long remissions exist. Cure is uncommon. |
How to use these numbers
- They describe groups. Your own stage, margin status, Ki-67, hormone pattern, and treatment plan all move your odds away from the group average.
- Margin status matters. A complete (R0) resection sits at the top of the range for any stage.
- High-volume center care matters. Outcomes are better at centers experienced in ACC.
- Ki-67 matters. A lower Ki-67 within any stage points to a better course on average.
- Hormones matter. Cortisol-making tumors tend to do a bit worse.
- Time matters. Return is most common in the first 2 to 3 years. Patients who stay clear past that window have better long-term odds.
What the numbers tend to mean by stage
Patients with stage I or II disease who get a complete removal at a high-volume center often live many years, and some are cured. Stage III patients commonly get years of control with the full plan: surgery, mitotane, sometimes radiation, and clinical trials as they open. Stage IV disease is harder. Long remissions happen, but cure is uncommon. The goal of treatment often shifts to controlling the cancer for as long as possible while keeping quality of life intact. Your team can give you a specific read on where you sit, based on your stage, margin status, Ki-67, and how the tumor has behaved. Ask for that conversation directly, and bring someone with you to take notes. Send follow-up questions in the days after, since a lot of what gets said in that visit is hard to take in at the time.
Questions to ask your team
Print or screenshot this page and bring it to your next visit. Writing your questions down ahead of time makes it easier to ask everything you meant to.
About the diagnosis and stage
- What is my ENSAT stage?
- Does my pathology report show a Weiss score and Ki-67? What are they?
- Did the surgery achieve clean margins (R0)?
- Has my case been discussed at a multidisciplinary tumor board?
- Would you recommend a pathology second opinion?
About the operation
- How many ACC surgeries have you done, and how many does this center do each year?
- Are you suggesting open or keyhole surgery, and why for my case?
- Does the plan take out any nearby tissue or organs as one piece (en-bloc)?
- Is there a hormone doctor on the team who works with mitotane?
About treatment after surgery
- Am I a candidate for adjuvant mitotane? Why or why not?
- Am I a candidate for adjuvant radiation?
- What is my steroid plan, and do I need a medical alert bracelet?
- What clinical trials are open at this center for my case?
About family and genetics
- Should I see a genetic counselor?
- Which genes will be tested?
- What would a positive result mean for my children, siblings, and parents?
About life and the path ahead
- Can I see a palliative care team alongside the main treatment?
- Is there a nurse navigator or social worker I can meet?
- Will any of this affect my fertility? Should I plan for that now?
- What does it look like if this plan works? If it does not?
- What is your honest sense of what is realistic for me?
Words to know
General cancer words live in the Cancer Basics guide. These are the ones used most in ACC care.
- Adrenocortical carcinoma (ACC)
- A cancer that starts in the cortex, the outer layer of the adrenal gland.
- Adrenal cortex
- The outer part of the adrenal gland. Normally makes cortisol, aldosterone, and androgens.
- Functional (or functioning) ACC
- An ACC that makes excess hormones.
- Nonfunctioning ACC
- An ACC that does not make excess hormones.
- Cushing syndrome
- The set of changes that comes from too much cortisol: weight gain in the trunk, easy bruising, high blood sugar, high blood pressure, mood changes.
- Pheochromocytoma
- A different adrenal tumor that pumps out adrenaline-type chemicals. Must be ruled out before any biopsy or surgery on an adrenal mass.
- Adrenal-protocol CT
- A CT done with a specific pattern of contrast timing to help tell benign from concerning adrenal masses.
- Weiss score
- A 9-point pathology scoring system used to separate ACC from a benign adrenal tumor. A score of 3 or more is consistent with ACC.
- Ki-67
- A marker of how fast tumor cells are dividing. Higher numbers point to more aggressive disease.
- ENSAT staging
- The European Network for the Study of Adrenal Tumors staging system for ACC. Stages I through IV.
- R0, R1, R2
- Margin status after surgery. R0 is complete removal with clean edges. R1 is microscopic cancer at the edge. R2 is visible cancer left behind.
- En-bloc resection
- Removing the tumor together with any involved nearby tissue or organs, as a single piece.
- Open radical adrenalectomy
- Removal of the adrenal gland through an open incision. The standard approach for most ACC.
- Tumor spill (rupture)
- Breaking the tumor capsule during surgery, which scatters cancer cells and worsens outcomes.
- Cytoreductive nephrectomy
- (General oncology term.) Surgery to debulk a primary tumor in someone who already has spread.
- Mitotane (Lysodren)
- An oral drug that selectively damages adrenal cortex cells. The only adrenal-specific drug therapy for ACC.
- Adjuvant therapy
- Treatment given after surgery to lower the chance of recurrence.
- EDP
- The chemotherapy regimen of etoposide, doxorubicin, and cisplatin. Given with mitotane as standard first-line for advanced ACC.
- FIRM-ACT trial
- The trial that established EDP plus mitotane as standard first-line for advanced ACC.
- ADIUVO trial
- The trial that supported observation (rather than adjuvant mitotane) for selected lower-risk ACC patients after complete surgery.
- Adrenal insufficiency
- Not enough cortisol. Universal in patients on mitotane and common after removal of a cortisol-making tumor.
- Glucocorticoid replacement
- A cortisol-type pill (usually hydrocortisone) taken daily to replace what the body cannot make.
- Mineralocorticoid replacement
- A salt-balancing pill (usually fludrocortisone) added when needed.
- Stress-dose steroids
- An extra dose of steroid taken during fever, illness, surgery, or vomiting, to prevent an adrenal crisis.
- High-volume center
- A hospital with experienced adrenal surgeons and a multidisciplinary team that sees ACC regularly.
- Multidisciplinary tumor board
- A regular meeting where a team reviews cases together: surgery, medical oncology, endocrinology, radiation oncology, pathology, radiology.
- Li-Fraumeni syndrome
- An inherited cancer syndrome from a TP53 gene change. Strongly linked to ACC, especially in younger patients.
- Lynch syndrome
- An inherited syndrome from a mismatch repair gene change. Linked to colon, uterine, urinary tract, and other cancers, including ACC.
- MEN1
- An inherited pattern of parathyroid, pancreatic, pituitary, and sometimes adrenal tumors.
- MSI-high / mismatch-repair-deficient
- Tumor features that point to Lynch syndrome and may respond to immunotherapy.
- Metastasectomy
- Surgery to remove one or a few spots of spread.
- Stereotactic body radiation
- Focused, high-dose radiation in a small number of visits.
- Palliative care
- Care for symptoms and quality of life that runs alongside cancer treatment. Not hospice.
- Hospice
- Comfort care when treatment for cancer control is no longer being pursued.
Sources and further reading
This guide draws on current society guidelines and the main trials behind the standard of care.
- European Society of Endocrinology / ENSAT ACC Guideline. academic.oup.com
- NCCN Neuroendocrine and Adrenal Tumors Guidelines. nccn.org
- American Association of Endocrine Surgeons Adrenalectomy Guidelines. endocrinesurgery.org
- FIRM-ACT trial (EDP plus mitotane in advanced ACC). nejm.org
- ADIUVO trial (adjuvant mitotane in lower-risk ACC). academic.oup.com
- NCI on Adrenocortical Carcinoma. cancer.gov
- American Cancer Society: Adrenal Cancer. cancer.org
- NCCN Patient Guidelines. nccn.org/patients
- Endocrine Society Pheochromocytoma Guideline (referenced for the safety rule-out before any biopsy). academic.oup.com
- Li-Fraumeni Syndrome (NCI fact sheet). cancer.gov
- Lynch Syndrome (NCI fact sheet). cancer.gov
- NIH Adrenal Cancer Information. niddk.nih.gov
- Get Palliative Care. getpalliativecare.org
- ClinicalTrials.gov. clinicaltrials.gov
- National Society of Genetic Counselors (find a counselor). nsgc.org
About this guide. Written by the WellPrept Clinical Team. Reviewed for adrenal cancer care up to date through 2026. Designed to be read alongside your care team's instructions.